Several therapeutic drugs targeting oxidative stress and inflammation are used for DKD treatment, including metformin, sodium-glucose cotransporter 2 (SGLT2) inhibitors, imeglimin, aspirin, cyclooxygenase-2 inhibitors, olmesartan, mineralocorticoid receptor antagonists (MRAs), and incretin-based agents. Here, PTGS2 is linked to diabetic kidney disease.